22nd Dec 2020 14:26
Open Orphan PLC - pharmaceutical services contract research organisation - Reports consultancy services contract with "top-three global pharmaceutical client" renewed until December 2021. "Through the Venn Life Sciences team in the Breda office in the Netherlands, Open Orphan provides independent, up-to-date and hands-on chemistry, manufacturing & control consultancy services to a leading global pharmaceutical client and has done since 2012," Open Orphan says.
Current stock price: 23.00 pence
Year-to-date change: five-times higher than 4.55p at the end of 2019
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ORPH.L